• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

生长激素腺瘤的影像学参数与临床和分子特征的相关性。

Association between radiological parameters and clinical and molecular characteristics in human somatotropinomas.

机构信息

Maimonides Institute of Biomedical Research of Cordoba, Córdoba, 14004, Spain.

Reina Sofia University Hospital (HURS), Córdoba, 14004, Spain.

出版信息

Sci Rep. 2018 Apr 18;8(1):6173. doi: 10.1038/s41598-018-24260-y.

DOI:10.1038/s41598-018-24260-y
PMID:29670116
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5906631/
Abstract

Acromegaly is a rare but severe disease, originated in 95% of cases by a growth hormone-secreting adenoma (somatotropinoma) in the pituitary. Magnetic resonance imaging (MRI) is a non-invasive technique used for the diagnosis and prognosis of pituitary tumours. The aim of this study was to determine whether the use of T2-weighted signal intensity at MRI could help to improve the characterisation of somatotropinomas, by analysing its relationship with clinical/molecular features. An observational study was implemented in a cohort of 22 patients (mean age = 42.1 ± 17.2 years; 59% women; 95% size>10 mm). Suprasellar-extended somatotropinomas presented larger diameters vs. non-extended tumours. T2-imaging revealed that 59% of tumours were hyperintense and 41% isointense adenomas, wherein hyperintense were more invasive (according to Knosp-score) than isointense adenomas. A higher proportion of hyperintense somatotropinomas presented extrasellar-growth, suprasellar-growth and invasion of the cavernous sinus compared to isointense adenomas. Interestingly, somatostatin receptor-3 and dopamine receptor-5 (DRD5) expression levels were associated with extrasellar and/or suprasellar extension. Additionally, DRD5 was also higher in hyperintense adenomas and its expression was directly correlated with Knosp-score and with tumour diameter. Hence, T2-weighted MRI on somatotropinomas represents a potential tool to refine their diagnosis and prognosis, and could support the election of preoperative treatment, when required.

摘要

肢端肥大症是一种罕见但严重的疾病,95%的病例源于垂体生长激素分泌腺瘤(生长激素瘤)。磁共振成像(MRI)是一种用于诊断和预测垂体肿瘤的非侵入性技术。本研究旨在通过分析其与临床/分子特征的关系,确定 MRI 上 T2 加权信号强度是否有助于改善生长激素瘤的特征。本研究实施了一项观察性研究,纳入了 22 名患者(平均年龄为 42.1±17.2 岁;59%为女性;95%的肿瘤直径>10mm)。鞍上扩展的生长激素瘤与非扩展肿瘤相比,直径更大。T2 成像显示,59%的肿瘤呈高信号,41%呈等信号腺瘤,高信号腺瘤的侵袭性(根据 Knosp 评分)高于等信号腺瘤。与等信号腺瘤相比,更多的高信号生长激素瘤存在颅外生长、鞍上生长和海绵窦侵袭。有趣的是,生长抑素受体 3 和多巴胺受体 5(DRD5)的表达水平与颅外和/或鞍上延伸有关。此外,高信号腺瘤中 DRD5 的表达也更高,其表达与 Knosp 评分和肿瘤直径直接相关。因此,生长激素瘤的 T2 加权 MRI 可能是一种潜在的工具,可以完善其诊断和预后,并在需要时支持术前治疗的选择。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db05/5906631/8f7b0ec155aa/41598_2018_24260_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db05/5906631/03e090885c6b/41598_2018_24260_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db05/5906631/4a3fa1dcfd06/41598_2018_24260_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db05/5906631/c8e4061df147/41598_2018_24260_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db05/5906631/8f7b0ec155aa/41598_2018_24260_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db05/5906631/03e090885c6b/41598_2018_24260_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db05/5906631/4a3fa1dcfd06/41598_2018_24260_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db05/5906631/c8e4061df147/41598_2018_24260_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db05/5906631/8f7b0ec155aa/41598_2018_24260_Fig4_HTML.jpg

相似文献

1
Association between radiological parameters and clinical and molecular characteristics in human somatotropinomas.生长激素腺瘤的影像学参数与临床和分子特征的相关性。
Sci Rep. 2018 Apr 18;8(1):6173. doi: 10.1038/s41598-018-24260-y.
2
Quantitative analyses of T2-weighted MRI as a potential marker for response to somatostatin analogs in newly diagnosed acromegaly.T2加权磁共振成像定量分析作为新诊断肢端肥大症对生长抑素类似物反应的潜在标志物
Endocrine. 2016 May;52(2):333-43. doi: 10.1007/s12020-015-0766-8. Epub 2015 Oct 16.
3
T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly.T2加权磁共振成像信号可预测肢端肥大症患者对生长抑素类似物的激素及肿瘤反应。
Endocr Relat Cancer. 2016 Nov;23(11):871-881. doi: 10.1530/ERC-16-0356. Epub 2016 Sep 20.
4
Truncated somatostatin receptor variant sst5TMD4 confers aggressive features (proliferation, invasion and reduced octreotide response) to somatotropinomas.截短的生长抑素受体变体sst5TMD4赋予生长激素瘤侵袭性特征(增殖、侵袭和奥曲肽反应降低)。
Cancer Lett. 2015 Apr 10;359(2):299-306. doi: 10.1016/j.canlet.2015.01.037. Epub 2015 Jan 28.
5
Pituitary MRI characteristics in 297 acromegaly patients based on T2-weighted sequences.基于T2加权序列的297例肢端肥大症患者的垂体MRI特征
Endocr Relat Cancer. 2015 Apr;22(2):169-77. doi: 10.1530/ERC-14-0305. Epub 2015 Jan 2.
6
Clinicopathological significance of baseline T2-weighted signal intensity in functional pituitary adenomas.功能性垂体腺瘤基线 T2 加权信号强度的临床病理意义。
Pituitary. 2018 Aug;21(4):347-354. doi: 10.1007/s11102-018-0877-3.
7
Resistant Paediatric Somatotropinomas due to AIP Mutations: Role of Pegvisomant.因 AIP 突变导致的耐药性儿科生长激素腺瘤:培维索孟的作用。
Horm Res Paediatr. 2018;90(3):196-202. doi: 10.1159/000488856. Epub 2018 Jun 28.
8
Growth hormone secreting pituitary adenomas show distinct extrasellar extension patterns compared to nonfunctional pituitary adenomas.生长激素型垂体腺瘤与无功能垂体腺瘤相比,具有明显的鞍外延伸模式。
Pituitary. 2022 Jun;25(3):480-485. doi: 10.1007/s11102-022-01217-z. Epub 2022 Mar 25.
9
Patterns of extrasellar extension in growth hormone-secreting and nonfunctional pituitary macroadenomas.生长激素分泌型和无功能垂体大腺瘤的鞍外扩展模式。
Neurosurg Focus. 2010 Oct;29(4):E4. doi: 10.3171/2010.7.FOCUS10155.
10
Acromegaly.肢端肥大症
Pituitary. 2006;9(4):297-303. doi: 10.1007/s11102-006-0409-4.

引用本文的文献

1
Quantitative and qualitative assessment of a pituitary neuroendocrine tumor's T2-signal intensity in acromegaly - a call for unification.肢端肥大症中垂体神经内分泌肿瘤T2信号强度的定量和定性评估——呼吁统一
Front Endocrinol (Lausanne). 2024 Nov 20;15:1441745. doi: 10.3389/fendo.2024.1441745. eCollection 2024.
2
The current state of MRI-based radiomics in pituitary adenoma: promising but challenging.基于 MRI 的脑垂体瘤放射组学的现状:前景广阔但极具挑战。
Front Endocrinol (Lausanne). 2024 Sep 20;15:1426781. doi: 10.3389/fendo.2024.1426781. eCollection 2024.
3
Prognostic Models in Growth-Hormone- and Prolactin-Secreting Pituitary Neuroendocrine Tumors: A Systematic Review.

本文引用的文献

1
AIP and the somatostatin system in pituitary tumours.垂体肿瘤中的芳香烃受体相互作用蛋白(AIP)与生长抑素系统
J Endocrinol. 2017 Dec;235(3):R101-R116. doi: 10.1530/JOE-17-0254. Epub 2017 Aug 23.
2
Contribution of molecular analysis to the typification of the non-functioning pituitary adenomas.分子分析对无功能垂体腺瘤分型的贡献。
PLoS One. 2017 Jul 10;12(7):e0180039. doi: 10.1371/journal.pone.0180039. eCollection 2017.
3
Changes in the management and comorbidities of acromegaly over three decades: the French Acromegaly Registry.
生长激素和催乳素分泌型垂体神经内分泌肿瘤的预后模型:一项系统综述
Diagnostics (Basel). 2023 Jun 19;13(12):2118. doi: 10.3390/diagnostics13122118.
4
Predicting Subtype of Growth Hormone Pituitary Adenoma based on Magnetic Resonance Imaging Characteristics.基于磁共振成像特征预测生长激素型垂体腺瘤亚型。
J Comput Assist Tomogr. 2022;46(1):124-130. doi: 10.1097/RCT.0000000000001249.
5
Molecular and Clinical Implications of Somatostatin Receptor Profile and Somatostatin Analogues Treatment in Oral Cavity Squamous Cell Carcinoma.生长抑素受体谱及生长抑素类似物治疗在口腔鳞状细胞癌中的分子及临床意义
Cancers (Basel). 2021 Sep 27;13(19):4828. doi: 10.3390/cancers13194828.
6
Usefulness of the Texture Signatures Based on Multiparametric MRI in Predicting Growth Hormone Pituitary Adenoma Subtypes.基于多参数磁共振成像的纹理特征在预测垂体生长激素腺瘤亚型中的应用价值
Front Oncol. 2021 Jul 7;11:640375. doi: 10.3389/fonc.2021.640375. eCollection 2021.
三十年来肢端肥大症的管理和合并症的变化:法国肢端肥大症登记处。
Eur J Endocrinol. 2017 May;176(5):645-655. doi: 10.1530/EJE-16-1064. Epub 2017 Feb 28.
4
Complications of acromegaly: cardiovascular, respiratory and metabolic comorbidities.肢端肥大症的并发症:心血管、呼吸及代谢共病
Pituitary. 2017 Feb;20(1):46-62. doi: 10.1007/s11102-017-0797-7.
5
BIM-23A760 influences key functional endpoints in pituitary adenomas and normal pituitaries: molecular mechanisms underlying the differential response in adenomas.BIM-23A760 影响垂体腺瘤和正常垂体的关键功能终点:腺瘤中差异反应的分子机制。
Sci Rep. 2017 Feb 9;7:42002. doi: 10.1038/srep42002.
6
T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly.T2加权磁共振成像信号可预测肢端肥大症患者对生长抑素类似物的激素及肿瘤反应。
Endocr Relat Cancer. 2016 Nov;23(11):871-881. doi: 10.1530/ERC-16-0356. Epub 2016 Sep 20.
7
Octreotide and pasireotide (dis)similarly inhibit pituitary tumor cells in vitro.奥曲肽和帕瑞肽在体外对垂体肿瘤细胞的抑制作用(不)相似。
J Endocrinol. 2016 Nov;231(2):135-145. doi: 10.1530/JOE-16-0332. Epub 2016 Sep 1.
8
Predictive value of T2 relative signal intensity for response to somatostatin analogs in newly diagnosed acromegaly.T2相对信号强度对新诊断肢端肥大症患者生长抑素类似物反应的预测价值
Neuroradiology. 2016 Nov;58(11):1057-1065. doi: 10.1007/s00234-016-1728-4. Epub 2016 Aug 11.
9
The Molecular Registry of Pituitary Adenomas (REMAH): A bet of Spanish Endocrinology for the future of individualized medicine and translational research.垂体腺瘤分子登记处(REMAH):西班牙内分泌学对个性化医学和转化研究未来的一次押注。
Endocrinol Nutr. 2016 Jun-Jul;63(6):274-84. doi: 10.1016/j.endonu.2016.03.001. Epub 2016 Apr 16.
10
Quantitative analyses of T2-weighted MRI as a potential marker for response to somatostatin analogs in newly diagnosed acromegaly.T2加权磁共振成像定量分析作为新诊断肢端肥大症对生长抑素类似物反应的潜在标志物
Endocrine. 2016 May;52(2):333-43. doi: 10.1007/s12020-015-0766-8. Epub 2015 Oct 16.